DNLIDenali Therapeutics Inc.
Is it safe?
Forensics clean, with a caveat: a safe balance sheet, but heavy debt (CCC) and big price swings.
Financially healthy, low distress risk Altman Z-score, a bankruptcy-risk model from five balance-sheet ratios.
Insiders were net sellers (-$435K, 90 days to Oct 8, 2026), selling is often routine.
Debt against weak or negative operating profit. A rule of thumb on leverage, not a credit rating.
Large price swings, high volatility. Worst drawdown -88% · now 27% below its 52-week high.
Unless marked, from SEC EDGAR, as of Dec 31, 2025.
Against the whole market›
Percentile against every name Ryufin tracks. Higher is better; the tick marks the middle of the market. Context, not one of the checks above.
Where this answer is blind. Altman sits structurally low for utilities and pipelines; Beneish runs high for fast growers, since sales growth alone lifts it; banks and REITs are excluded.
Can DNLI take a bad year?
The deepest fall in DNLI's price history on file is −88%; it is 27% below its high today.
Altman Z-score · distress below 1.8 · safe above 3 · safe zone, the balance sheet is not what threatens this one
- Cash runway
- 1.6 years
Cash runway · burning $110M a quarter at the current rate
- Annualised volatility
- 60%
Annualised volatility · roughly twice as jumpy as the market
- Worst drawdown on file
- −88%
Worst drawdown on file · −27% today
Details›
- Cash and short-term investments
- $710M
- EBITDA, trailing twelve months
- −$533M
- Operating profit, trailing twelve months
- −$543M
- Annualised volatilitytwo years of daily moves
- 60%
- Worst drawdown on file
- −88%
- Below its 52-week high
- 27%
Balance sheet from SEC filings; drawdown and volatility from end-of-day closes; Altman Z from the filed statements.